Rare diseases affect nearly 300 million people globally with most patients aged five or less. Traditional diagnostic approaches have provided much of the diagnosis; however, there are limitations. For instance, simply inadequate and untimely diagnosis adversely affects both the patient and their families. This review advocates the use of whole genome sequencing in clinical settings for diagnosis of rare genetic diseases by showcasing five case studies. These examples specifically describe the utilization of whole genome sequencing, which helped in providing relief to patients via correct diagnosis followed by use of precision medicine.
Simone BaldovinoMDDomenica TaruscioMDDario RoccatelloMD.Rare diseases in Europe: from a wide to a local perspective. Isr Med Assoc J2016;
18:359–63
2.
BickDJonesMTaylorSLTaftRJBelmontJ.Case for genome sequencing in infants and children with rare, undiagnosed or genetic diseases. J Med Genet2019;
56:783–91
3.
WakapSNLambertDMOlryARodwellCGueydanCLanneauVMurphyDLe CamYRathA.Estimating cumulative point prevalence of rare diseases: analysis of the orphanet database. Eur J Hum Genet2020;
28:165–73
4.
AustinCPCutilloCMLauLPLJonkerAHRathAJulkowskaDThomsonDTerrySFde MontleauBArdigòD.Future of rare diseases research 2017–2027: an IRDiRC perspective. Clin Transl Sci2018;
11:21–7
5.
DawkinsHJSDraghia‐AkliRLaskoPLauLPLJonkerAHCutilloCMRathABoycottKMBaynamGLochmüllerH.Progress in rare diseases research 2010–2016: an IRDiRC perspective. Clin Transl Sci2018;
11:11–20
6.
HartleyTBalcıTBRojasSKEatonACanadaCRDymentDABoycottKM.The unsolved rare genetic disease atlas? An analysis of the unexplained phenotypic descriptions in OMIM®. Am J Med Genet C Semin Med Genet2018;
178:458–63
7.
JacobsPAStrongJA.A case of human intersexuality having a possible XXY sex-determining mechanism. Nature1959;
183:302–3
8.
LejeuneJ.Study of somatic chromosomes from 9 mongoloid children. CR Hebd Seances Acad Sci1959;
248:1721–2
9.
ShafferLGBejjaniBA.Medical applications of array CGH and the transformation of clinical cytogenetics. Cytogenet Genome Res2006;
115:303–9
10.
WiegantJRiedTNederlofPMPloegMVdTankeHJRaapAK.In situ hybridisation with fluoresceinated DNA. Nucl Acids Res1991;
19:3237–41
11.
LangerPRWaldropAAWardDC.Enzymatic synthesis of biotin-labeled polynucleotides: novel nucleic acid affinity probes. Proc Natl Acad Sci U S A1981;
78:6633–7
12.
BeliveauBJJoyceEFApostolopoulosNYilmazFFonsekaCYMcColeRBChangYLiJBSenaratneTNWilliamsBR.Versatile design and synthesis platform for visualizing genomes with oligopaint FISH probes. Proc Natl Acad Sci USA2012;
109:21301–6
13.
MaciejewskiJPMuftiGJ.Whole-genome scanning as a cytogenetic tool in hematologic malignancies. Blood2008;
112:965–74
14.
LuXShawCAPatelALiJCooperMLWellsWRSullivanCMSahooTYatsenkoSABacinoCA.Clinical implementation of chromosomal microarray analysis: summary of 2513 postnatal cases. PLoS One2007;
2:e327
15.
BoycottKMVanstoneMRBulmanDEMacKenzieAE.Rare-disease genetics in the era of next-generation sequencing: discovery to translation. Nat Rev Genet2013;
14:681–91
16.
NgSBTurnerEHRobertsonPDFlygareSDBighamAWLeeCShafferTWongMBhattacharjeeAEichlerEE.Targeted capture and massively parallel sequencing of 12 human exomes. Nature2009;
461:272–6
17.
NgSBBuckinghamKJLeeCBighamAWTaborHKDentKMHuffCDShannonPTJabsEWNickersonDA.Exome sequencing identifies the cause of a mendelian disorder. Nat Genet2010;
42:30–5
18.
NgSBBighamAWBuckinghamKJHannibalMCMcMillinMJGildersleeveHIBeckAETaborHKCooperGMMeffordHC.Exome sequencing identifies MLL2 mutations as a cause of kabuki syndrome. Nat Genet2010;
42:790–3
19.
ChengAYTeoY-YOngRT-H.Assessing single nucleotide variant detection and genotype calling on whole-genome sequenced individuals. Bioinformatics2014;
30:1707–13
20.
BeckTFMullikinJCBieseckerLG.Systematic evaluation of sanger validation of next-generation sequencing variants. Clin Chem2016;
62:647–54
21.
BhattacharjeeASokolskyTWymanSKReeseMGPuffenbergerEStraussKMortonHParadRBNaylorEW.Development of DNA confirmatory and high-risk diagnostic testing for newborns using targeted next-generation DNA sequencing. Genet Med2015;
17:337–47
22.
Saudi Mendeliome Group.
Comprehensive gene panels provide advantages over clinical exome sequencing for mendelian diseases. Genome Biol2015;
16:134
23.
SodenSESaundersCJWilligLKFarrowEGSmithLDPetrikinJELePichonJ-BMillerNAThiffaultIDinwiddieDL.Effectiveness of exome and genome sequencing guided by acuity of illness for diagnosis of neurodevelopmental disorders. Sci Transl Med2014;
6:265ra168
24.
RumpPJazayeriOvan Dijk-BosKKJohanssonLFvan EssenAJVerheijJBGMVeenstra-KnolHERedekerEJWMannensMMAMSwertzMA.Whole-exome sequencing is a powerful approach for establishing the etiological diagnosis in patients with intellectual disability and microcephaly. BMC Med Genomics2015;
9:1–9
25.
TammimiesKMarshallCRWalkerSKaurGThiruvahindrapuramBLionelACYuenRKCUddinMRobertsWWeksbergR.Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder. Jama2015;
314:895–903
26.
WajidBSohailMUEktiARSerpedinE.The A, C, G, and T of genome assembly. Biomed Res Int2016;
2016:6329217
27.
WajidBSerpedinENounouMNounouH.MARAGAP: a modular approach to reference assisted genome assembly pipeline. Ijcbdd2015;
8:226–50
28.
WajidBSerpedinE.Do it yourself guide to genome assembly. Brief Funct Genom2016;
15:1–9
29.
WajidBSerpedinENounouMNounouH.Optimal reference sequence selection for genome assembly using minimum description length principle. EURASIP J Bioinform Syst Biol2012;
2012:1–11
30.
WajidBSerpedinE.Review of general algorithmic features for genome assemblers for next generation sequencers. Genomics Proteomics Bioinformatics2012;
10:58–73
31.
BelkadiABolzeAItanYCobatAVincentQBAntipenkoAShangLBoissonBCasanovaJ-LAbelL.Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci USA2015;
112:5473–78
32.
MeynertAMAnsariMFitzPatrickDRTaylorMS.Variant detection sensitivity and biases in whole genome and exome sequencing. BMC Bioinformatics2014;
15:1–11
33.
MeienbergJBruggmannROexleKMatyasG.Clinical sequencing: is WGS the better WES?Hum Genet2016;
135:359–62
34.
BoycottKMHartleyTBieseckerLGGibbsRAInnesAMRiessOBelmontJDunwoodieSLJojicNLassmannT.A diagnosis for all rare genetic diseases: the horizon and the next frontiers. Cell2019;
177:32–37
35.
SchwarzeKBuchananJFermontJMDreauHTilleyMWTaylorJMAntoniouPKnightSJLCampsCPentonyMM.The complete costs of genome sequencing: a microcosting study in cancer and rare diseases from a single center in the United Kingdom. Genet Med2020;
22:85–94
36.
LionelACCostainGMonfaredNWalkerSReuterMSHosseiniSMThiruvahindrapuramBMericoDJoblingRNalpathamkalamT.Improved diagnostic yield compared with targeted gene sequencing panels suggests a role for whole-genome sequencing as a first-tier genetic test. Genet Med2018;
20:435–43
37.
WrightCFFitzgeraldTWJonesWDClaytonSMcRaeJFVan KogelenbergMKingDAAmbridgeKBarrettDMBayzetinovaT.Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. Lancet2015;
385:1305–14
38.
CummingSAHamiltonMJRobbYGregoryHMcWilliamCCooperAAdamBMcGhieJHamiltonGHerzykP.De novo repeat interruptions are associated with reduced somatic instability and mild or absent clinical features in myotonic dystrophy type 1. Eur J Hum Genet2018;
26:1635–47
39.
MitsuhashiSNakagawaSUedaMTImanishiTFrithMCMitsuhashiH.Nanopore-based single molecule sequencing of the D4Z4 array responsible for facioscapulohumeral muscular dystrophy. Sci Rep2017;
7:1–8
40.
MizuguchiTSuzukiTAbeCUmemuraATokunagaKKawaiYNakamuraMNagasakiMKinoshitaKOkamuraY.A 12-kb structural variation in progressive myoclonic epilepsy was newly identified by long-read whole-genome sequencing. J Hum Genet2019;
64:359–68
41.
MerkerJDWengerAMSneddonTGroveMZappalaZFresardLWaggottDUtiramerurSHouYSmithKS.Long-read genome sequencing identifies causal structural variation in a mendelian disease. Genet Med2018;
20:159–63
42.
GonçalvesAOliveiraJCoelhoTTaipaRMelo-PiresMSousaMSantosR.Exonization of an intronic LINE-1 element causing Becker muscular dystrophy as a novel mutational mechanism in dystrophin gene. Genes (Basel)2017;
8:253
43.
WallaceDC.Mitochondrial DNA variation in human radiation and disease. Cell2015;
163:33–38
44.
KrishnanKJReeveAKSamuelsDCChinneryPFBlackwoodJKTaylorRWWanrooijSSpelbrinkJNLightowlersRNTurnbullDM.What causes mitochondrial DNA deletions in human cells?Nat Genet2008;
40:275–9
45.
JacobsLJJongbloedRJWijburgFAde KlerkJBGeraedtsJPNijlandJGScholteHRde CooIFSmeetsHJ.Pearson syndrome and the role of deletion dimers and duplications in the mtDNA. J Inherit Metab Dis2004;
27:47–55
46.
DuranGPMartinez-AguayoAPoggiHLagosMGutierrezDHarrisPR.Large mitochondrial DNA deletion in an infant with Addison disease. JIMD Reports-Case and Research Reports, 2011/3. Berlin: Springer, 2011, pp.5–9.
47.
WisniewskiKEZhongNPhilippartM.Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology2001;
57:576–81
48.
RayDABatzerMA.Reading TE leaves: new approaches to the identification of transposable element insertions. Genome Res2011;
21:813–20
49.
FinkelRSChiribogaCAVajsarJDayJWMontesJDe VivoDCYamashitaMRigoFHungGSchneiderE.Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet2016;
388:3017–26
50.
FinkelRSMercuriEDarrasBTConnollyAMKuntzNLKirschnerJChiribogaCASaitoKServaisLTizzanoE.Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med2017;
377:1723–32
51.
KimJHuCMoufawad El AchkarCBlackLEDouvilleJLarsonAPendergastMKGoldkindSFLeeEAKuniholmA.Patient-customized oligonucleotide therapy for a rare genetic disease. N Engl J Med2019;
381:1644–52
52.
ThenappanTOrmistonMLRyanJJArcherSL.Pulmonary arterial hypertension: pathogenesis and clinical management. Bmj2018;
360:j5492
53.
PortilloKSantosSMadrigalIBlancoIParéCBorderíasLPeinadoVIRocaJMilàMBarberàJA.Study of the BMPR2 gene in patients with pulmonary arterial hypertension. Arch Bronconeumol2010;
46:129–34.
NorisMRemuzziG.Atypical hemolytic–uremic syndrome. N Engl J Med2009;
361:1676–87
56.
VanierMTDuthelSRodriguez-LafrasseCPentchevPCarsteaED.Genetic heterogeneity in Niemann-Pick C disease: a study using somatic cell hybridization and linkage analysis. Am J Hum Genet1996;
58:118–25
57.
VanierMT.Niemann-Pick disease type C. Orphanet J Rare Dis2010;
5:1–18
58.
HildrethAWigbyKChowdhurySNahasSBareaJOrdonezPBatalovSDimmockDKingsmoreS; RCIGM Investigators.
Rapid whole-genome sequencing identifies a novel homozygous NPC1 variant associated with Niemann–Pick type C1 disease in a 7-week-old male with cholestasis. Cold Spring Harb Mol Case Stud2017;
3:a001966
59.
LiuBTurleySDBurnsDKMillerAMRepaJJDietschyJM.Reversal of defective lysosomal transport in NPC disease ameliorates liver dysfunction and neurodegeneration in the npc1−/− mouse. Proc Natl Acad Sci USA2009;
106:2377–82
60.
FinkJKRavinPDFilling-KatzMArgoffCEHallettM.Clinical and genetic analysis of progressive dystonia with diurnal variation. Arch Neurol1991;
48:908–11
61.
FurukawaYGuttmanMSparaganaSPTrugmanJMHylandKWyattPLangAERouleauGAShimadzuMKishSJ.Dopa‐responsive dystonia due to a large deletion in the GTP cyclohydrolase I gene. Ann Neurol2000;
47:517–20
62.
BainbridgeMNWiszniewskiWMurdockDRFriedmanJGonzaga-JaureguiCNewshamIReidJGFinkJKMorganMBGingrasM-C.Whole-genome sequencing for optimized patient management. Sci Transl Med2011;
3:87re3–87re3
63.
StranneheimHLagerstedt-RobinsonKMagnussonMKvarnungMNilssonDLeskoNEngvallMAnderlidBMArnellHJohanssonCBBarbaroMBjörckEBruhnHEisfeldtJFreyerCGrigelionieneGGustavssonPHammarsjöAHellström-PiggMIwarssonEJemtALaaksonenMEnokssonSLMalmgrenHNaessKNordenskjöldMOscarsonMPetterssonMRasiCRosenbaumASahlinESardhEStödbergTTesiBThamEThonbergHTöhönenVvon DöbelnUVassiliouDVonlanthenSWikströmACWincentJWinqvistOWredenbergAYgbergSZetterströmRHMaritsPSollerMJNordgrenAWirtaVLindstrandAWedellA.Integration of whole genome sequencing into a healthcare setting: high diagnostic rates across multiple clinical entities in 3219 rare disease patients. Genome Med2021;
13:40
64.
TurroEAstleWJMegyKGräfSGreeneDShamardinaOAllenHLSanchis-JuanAFrontiniMThysCStephensJMapetaRBurrenOSDownesKHaimelMTunaSDeeviSVVAitmanTJBennettDLCallejaPCarssKCaulfieldMJChinneryPFDixonPHGaleDPJamesRKoziellALaffanMALevineAPMaherERMarkusHSMoralesJMorrellNWMumfordADOrmondroydERankinSRendonARichardsonSRobertsIRoyNBASaleemMASmithKGCStarkHTanRYYThemistocleousACThrasherAJWatkinsHWebsterARWilkinsMRWilliamsonCWhitworthJHumphraySBentleyDRKingstonNWalkerNBradleyJRAshfordSPenkettCJFresonKStirrupsKERaymondFLOuwehandWH; NIHR BioResource for the 100,000 Genomes Project.Whole-genome sequencing of patients with rare diseases in a national health system. Nature2020;
583:96–102
65.
van DiemenCCKerstjens-FrederikseWSBergmanKAde KoningTJSikkema-RaddatzBvan der VeldeJKAbbottKMHerkertJCLöhnerKRumpPMeems-VeldhuisMTNeerincxPBTJongbloedJDHvan Ravenswaaij-ArtsCMSwertzMASinkeRJvan LangenIMWijmengaC.Rapid targeted genomics in critically ill newborns. Pediatrics2017;
140:e20162854
66.
MarshallCRBickDBelmontJWTaylorSLAshleyEDimmockDJobanputraVKearneyHMKulkarniSRehmH.The medical genome initiative: moving whole-genome sequencing for rare disease diagnosis to the clinic. Genome Med2020;
12:1–4
